Who Should Attend

This educational activity is designed to meet the educational needs of medical and radiation oncologists, thoracic surgeons, nurses, diagnostic radiologists, pathologists, pulmonologists, researchers, and other healthcare professionals interested in the care and treatment of patients with thoracic malignancies.

Learning Objectives

After attending Perspectives in Thoracic Oncology 2018, participants should be able to:

  • Describe the impact of lung cancer staging system revisions, molecular testing guideline updates, novel imaging and diagnostic techniques, and the role of liquid biopsy/cell free DNA on patient evaluation practices
  • Review the current and emerging clinical data regarding the treatment NSCLC that harbor genetic mutations such as EGFR, ALK, ROS1, and less commonly ERBB2, HER2, BRAF, KRAS, MET, TRK, and RET
  • Determine the clinical relevance of emerging efficacy and safety data from trials evaluating targeted therapies and immune checkpoint inhibitors (alone or in combination) for NSCLC, SCLC, mesothelioma, and less common thoracic malignancies
  • Evaluate the role of current and emerging biomarkers as predictive indicators for treatment selection and patient response
  • Translate the latest evidence regarding molecularly targeted agents, immunotherapies, and predictive biomarkers to informed and personalized NSCLC treatment plans

Continuing Education

Imedex is accredited by the ACCME to provide continuing medical education for physicians.

In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Statements

PHYSICIANS

Imedex designates this live activity for a maximum of 12.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MAINTENANCE OF CERTIFICATION - ABIM

Successful completion of this CME activity enables a participant to earn up to 12.0 MOC points towards the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points. The deadline to claim MOC points is December 13, 2018.  ABIM Diplomates will be asked to provider their identification number and DOB.

PHARMACY

This live, knowledge-based activity (Universal Activity Number: JA0006201-9999-18-089-L01-P) has been approved for a maximum of 12.0 contact hours (1.2 CEUs).

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system. The deadline to claim credit is December 13, 2018.  Following ACPE Policy, NACCME will not be able to report your claimed credit to CPE Monitor after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.

NURSING         

This continuing nursing education activity awards 12.0 contact hours. This activity will also award pharmacotherapeutic contact hours, however the final assignment of these contact hours will be announced once all content has been approved.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 12.0 contact hours.

PHYSICIAN ASSISTANTS

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 12.0 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.